KR20190050037A - Antimicrobial composition including extract of schizophyllum commune strain culture and preparing method thereof - Google Patents

Abstract

The present invention relates to an antibacterial composition containing a Schizophyllum commune strain culture extract, which is effective for controlling and preventing a plant disease, and a preparing method thereof. The antibacterial composition comprises a Schizophyllum commune strain culture extract containing schizostatin or a derivative thereof.

Description

FIELD OF THE INVENTION [0001] The present invention relates to an antimicrobial composition containing a culture extract of Rhizoma mushroom strain and an antimicrobial composition containing the same,

The present invention relates to an antimicrobial composition containing a culture extract of Rhizoma mushroom strain and a method for producing the same.

As the term "well being" or "lifestyle of health and sustainability" (LOHAS) is used in recent years, there is an increasing tendency to pursue and practice healthy living and environmental preservation around the world. Among them, dietary habits, especially agricultural products, are strongly related to health and are directly affected by their consumption, so they are sensitive to these changes. Since 2000, Korea has been suffering from environmental disasters such as yellow sand, mad cow disease, Consumer interest in safe food is increasing. As a result, the preference for environmentally friendly agricultural products is growing, and there is an increasing interest and research on biological control such as biological pesticides for cultivation of environmentally friendly agricultural products.

On the other hand, existing methods of controlling pathogenic fungi in crops include partial resistance breeding, cultivation, and the use of chemical antifungal agents. However, new varieties are time - consuming, pathogens adapt to plant resistance, mutagenic effects are short, and crop rotation and soil sunlight therapy are difficult to implement in large - scale agriculture. It is also reported that chemical antifungal agents are less effective than cost and adversely affect the environment and human health. Among them, chemical antifungal agents (agricultural pesticides) have been emphasized in terms of improving the yield and quality of crops and increasing the supply amount according to population increase. Up to now, chemical control through chemical fertilizers and organic synthetic pesticides It was done. However, the residual toxicity of degradation due to the excessive use of pesticides has been adversely affecting the environment and ecosystem by polluting the air, soil, and groundwater, and the side effects such as reduction of medicinal effect due to acquisition of pesticide resistance of plant pathogens are increasing. As a biological control method using a microbial agent for such side effects, Bacillus spp., Pseudomonas spp., Streptomyces spp., And Streptomyces spp. (Fusarium spp.) Have been studied in the field of microbial control of soil-borne pathogens. The biological control method is considered to be an effective countermeasure in that it has no residual toxicity and does not disturb the agricultural ecosystem, but the proportion of biological control in the global pesticide market is still low.

Mushrooms, which are low-calorie healthy foods rich in dietary fiber and protein, are mainly used for edible and medicinal purposes. Mushrooms have been reported to produce a variety of functional substances such as anticancer, anticholesterol, blood pressure regulators, immunomodulators, as well as antibiotics and antiviral substances. Therefore, mushrooms are widely used as a substitute for chemical pesticides.

On the other hand, the skirt mushroom belongs to the skirt mushroom, and the scapula has a fan-shaped or skirt-like shape having a diameter of about 1 cm to 3 cm, and the surface has thick white, gray or grayish brown hairs. The girth is divided by the number of wrinkles. Fruiting body tissue is leather and shrinks when dry or wet. The wrinkles are white or grayish white, and the ends of the wrinkles are smooth and double. There is no stand, and a part of gad lives on attachment to the host. Spores are aspheric, 5 ~ 6 ㎛ × 4 ~ 5 ㎛, with smooth surface and light color. Form consultation is fleshy. The cyst is spindle-shaped, with no horns at the top, and the length is 60 ㎛ to 80 ㎛. It is a buhyeongseong mushroom that breaks up or overlaps on dead wood or living tree bark all the seasons and disintegrates the tree. It occurs from spring to autumn, forming a cluster of overlapping groups. It is difficult to use as a mushroom of horny mushroom for edible purposes, but there have been reported many cases of extracting polysaccharides from liquid cultured mycelium or culture of purely isolated mycelium.

Korean Patent Laid-Open No. 10-2012-0091680 discloses Streptomyces sp. A1009 having excellent antimicrobial activity against plant pathogenic bacteria and a method of culturing the same.

Disclosure of Invention Technical Problem [8] Accordingly, the present invention has been made to solve the above-mentioned problems occurring in the prior art, and it is an object of the present invention to provide an antimicrobial composition effective for controlling and preventing plant diseases and a method for producing the same.

It should be understood, however, that the technical scope of the embodiments of the present invention is not limited to the above-described technical problems, and other technical problems may exist.

As a technical means for achieving the above-mentioned technical object, the first aspect of the present invention provides an antimicrobial composition comprising a cultured extract of Schizosaccharomyces strains containing schizostatin or a derivative thereof.

According to one embodiment of the present invention, the chiostatin or a derivative thereof may include, but is not limited to, a substance represented by the following formula (1);

[Chemical Formula 1]

Wherein R ₁ to R ₃ are each independently selected from the group consisting of hydrogen, oxygen, a hydroxyl group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted cycloalkyl group, A substituted or unsubstituted alkoxy group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryloxy group, or a substituted or unsubstituted alkoxycarbonyl group, and n is a number of 1 to 6].

According to one embodiment of the present invention, the chiostatin or derivative thereof may include, but is not limited to, a substance represented by the following formula (2);

(2)

.

.

According to one embodiment of the present invention, the chiostatin or a derivative thereof may include, but is not limited to, a substance represented by the following formula (3);

(3)

.

.

According to one embodiment of the present invention, the chiostatin or a derivative thereof may include, but is not limited to, a substance represented by the following Chemical Formula 4;

[Chemical Formula 4]

.

.

According to one embodiment of the present invention, the chiostatin or a derivative thereof may include, but is not limited to, a substance represented by the following formula (5);

[Chemical Formula 5]

.

.

According to one embodiment of the present invention, the chiostatin or derivative thereof may include, but is not limited to, a substance represented by the following formula (6);

[Chemical Formula 6]

.

.

According to a second aspect of the present invention, there is provided a method for cultivating a skim mushroom strain on a medium; Obtaining a first extract from the cultured skim mushroom strain using a first solvent; And extracting chizostatin or a derivative thereof from the first extract using a second solvent.

According to one embodiment of the present invention, the medium may be a PDA (potato dextrose agar), a PDA (potato dextrose broth), a SDA (sabouraud dextrose agar), a DSA (dextrose starch agar) , CDA (czapek dox agar), or CMC (carboxyl methyl cellulose), but the present invention is not limited thereto.

According to one embodiment of the present invention, the first solvent may be selected from the group consisting of water, acetone, C ₁ -C ₄ alcohol or a mixed solvent thereof, and combinations thereof, but is not limited thereto.

According to one embodiment of the present invention, the second solvent may include, but is not limited to, an organic solvent.

According to one embodiment of the present invention, the extraction of the chiostatin or derivative thereof may be performed by extraction, distribution of water, or chromatography, but is not limited thereto.

The above-described task solution is merely exemplary and should not be construed as limiting the present disclosure. In addition to the exemplary embodiments described above, there may be additional embodiments in the drawings and the detailed description of the invention.

According to the above-mentioned object of the present invention, the present invention can provide an antimicrobial composition and a method for producing the same.

The antimicrobial composition according to the present invention is a compound derived from a natural material and exhibits an antifungal effect on a phytopathogenic fungus, thereby preventing and preventing plant diseases.

In particular, the antifungal effect of the novel compounds isolated from the culture of the skim mushroom strain was confirmed, and it is possible to use them for the control and prevention of fungal diseases.

BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a flow chart of a method of making an antimicrobial composition according to one embodiment of the present invention.
2 is a microscope image showing antimicrobial activity of the antimicrobial composition according to one embodiment of the present invention.

Hereinafter, embodiments of the present invention will be described in detail with reference to the accompanying drawings so that those skilled in the art can easily carry out the present invention.

It should be understood, however, that the present invention may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. In the drawings, the same reference numbers are used throughout the specification to refer to the same or like parts.

Throughout this specification, when a part is referred to as being "connected" to another part, it is not limited to a case where it is "directly connected" but also includes the case where it is "electrically connected" do.

It will be appreciated that throughout the specification it will be understood that when a member is located on another member "top", "top", "under", "bottom" But also the case where there is another member between the two members as well as the case where they are in contact with each other.

Throughout this specification, when an element is referred to as " including " an element, it is understood that the element may include other elements as well, without departing from the other elements unless specifically stated otherwise.

As used herein, the terms " about, " " substantially, " and the like are used herein to refer to or approximate the numerical value of manufacturing and material tolerances inherent in the stated sense, Accurate or absolute numbers are used to prevent unauthorized exploitation by unauthorized intruders of the mentioned disclosure. Also, throughout the present specification, the phrase " step " or " step " does not mean " step for.

Throughout this specification, the term " combination thereof " included in the expression of the machine form means one or more combinations or combinations selected from the group consisting of the constituents described in the expression of the machine form, And the like.

Throughout this specification, the description of "A and / or B" means "A, B, or A and B".

Illustrative examples of such substituents are set forth below, but are not limited thereto.

As used herein, the term " substituted or unsubstituted " A hydroxyl group; An alkyl group; An alkenyl group; An alkynyl group; Cycloalkyl groups; An alkoxy group; A heterocyclic group; An aralkyl group; An aryloxy group; An alkoxycarbonyl group, or a substituted or unsubstituted group in which at least two of the above-exemplified substituents are connected to each other. For example, the "substituent group to which at least two substituents are connected" may be a heterocyclic group substituted with an alkyl group or an alkyl group substituted with a heterocyclic group.

In the present specification, the alkyl group means a saturated aliphatic hydrocarbon group containing from 1 to 20 (for example, 2 to 18, 3 to 18, 1 to 8, 1 to 6, 1 to 4 or 1 to 3) carbon atoms do. The alkyl group may be linear, branched, cyclic or any combination thereof. Specific examples of the alkyl group include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-heptyl or 2-ethylhexyl. The alkyl group may be substituted (i.e., optionally substituted) with one or more substituents, or it may be a multiple ring as described below.

As used herein, an alkenyl group refers to an aliphatic carbon group containing from 2 to 20 (e.g., 2 to 18, 2 to 8, 2 to 6, or 2 to 4) carbon atoms and at least one double bond do. Like the alkyl group, the alkenyl group may be linear, branched or cyclic or any combination thereof. Specific examples of the alkenyl group include, but are not limited to, allyl, isoprenyl, 2-butenyl, and 2-hexenyl. The alkenyl group may be optionally substituted with one or more substituents as described below.

As used herein, an alkynyl group means an aliphatic carbon group containing from 2 to 20 (for example, from 2 to 8, from 2 to 6 or from 2 to 4) carbon atoms and having at least one triple bond. The alkynyl group may be linear, branched or cyclic, or any combination thereof. Specific examples of the alkynyl group include, but are not limited to, propargyl and butanyl. The alkynyl group may be optionally substituted with one or more substituents as described below.

In the present specification, the cycloalkyl group is not particularly limited, but preferably has 3 to 60 carbon atoms (e.g., 3 to 30, 3 to 20, and 3 to 6 carbon atoms). Specific examples of the cycloalkyl group include cyclopropyl, cyclobutyl, cyclopentyl, 3-methylcyclopentyl, 2,3-dimethylcyclopentyl, cyclohexyl, 3-methylcyclohexyl, 4-methylcyclohexyl, 2,3-dimethyl But are not limited to, cyclohexyl, 3,4,5-trimethylcyclohexyl, 4-tert-butylcyclohexyl, cycloheptyl, cyclooctyl.

In the present specification, the heterocyclic group is a heterocyclic group and is a heterocyclic group containing at least one of N, P, O, S, Se, Ge and Si, and the number of carbon atoms is not particularly limited but is preferably 2 to 60 carbon atoms. Specific examples of the heterocyclic group include a thiophene group, a furan group, a pyrrolyl group, an imidazole group, a thiazole group, an oxazole group, an oxadiazole group, a triazole group, a pyridyl group, a bipyridyl group, a pyrimidine group, , An acridine group, a carbolinyl group, an acenaphthopyranyl group, an acenaphthoquinoxaline group, an indenoquinazoline group, an indenoisoquinoline group, an indenoquinoline group, a pyridone ring, a pyridazine group, a pyrazine group, A benzoyl group, a benzoyl group, a benzooxazole group, a benzooxazole group, a benzooxazole group, a benzooxazole group, a benzooxazole group, a benzooxazole group, a benzooxazole group, a benzooxazole group, A benzothiazole group, a dibenzofurane group, a phenanthroline group, a thiazolyl group, an isoxazolyl group, a benzothiazole group, a benzothiazole group, a benzoxazole group, a dibenzocarbazole group, a benzothiophene group, Group, an oxadiazolyl group, a thiadiazolyl group, benzothiazole A benzopyrimidine group, a pyridoxine group, a phenoxazinyl group, a benzothiazyl group, a dibenzofuranyl group, a benzoquinazoline group, a pyridopyrimidine group, an indazole group, a benzopiperimidinone group, It is not. The heterocyclic group includes an aliphatic heterocyclic group and an aromatic heterocyclic group.

As used herein, an aryl group used alone or as part of a larger moiety, such as in an aralkyl group, an alkoxy group or an aryloxy group, may have a single ring (e.g., phenyl), a double ring (e.g., indenyl, (E. G., Fluorenyltetrahydrofuranyl, or tetrahydroanthracenyl, anthracenyl) ring system, wherein a single ring (e.g., The system is aromatic or at least one of the rings in the double ring or triple ring system is aromatic. The double ring and triple ring groups include benzo fused two to three membered carbocyclic rings. For example, a benzo fused group includes phenyl fused with two or more C _4-8 carbocyclic moieties. The aryl may be optionally substituted with one or more substituents as described below.

In this specification, an alkoxycarbonyl group refers to -COOR, wherein R is alkyl as defined above, e.g., methoxycarbonyl, ethoxycarbonyl, and the like.

As used herein, an alkoxy group refers to an alkyl-O- group, wherein " alkyl " is as previously defined.

As used herein, the term "antibacterial activity" or "antibacterial activity" refers to a property of resistance to microorganisms such as bacteria or fungi. More specifically, the term "antimicrobial activity" means a property of inhibiting the growth or proliferation of pathogenic fungi do.

As used herein, the term " antimicrobial composition " is a composition having an activity of inhibiting the growth of microorganisms such as bacteria or fungi, and may include all forms used in various fields requiring an antimicrobial effect. For example, , Quasi-drugs, food additives or feed additives, and the like. Specifically, in medicines, antibiotics and antifouling agents are used for the same purpose, for foods, for preservation and antibacterial purposes, for agriculture, for antibacterial, sterilizing and disinfecting purposes, for cosmetics and household products for dandruff, for athlete's foot, It may be used for products directly related to microorganisms such as detergent, anti acne, etc., or may be used for preservative, antimicrobial or sterilizing purposes, for example, for cleaning detergent or dishwashing detergent.

Hereinafter, the antimicrobial composition of the present invention and a method of producing the same will be described in detail with reference to embodiments, examples and drawings. However, the present invention is not limited to these embodiments and examples and drawings.

A first aspect of the present invention relates to an antimicrobial composition comprising a cultured extract of Schizosaccharomyces strains containing schizostatin or a derivative thereof.

The skirt mushroom belongs to the skirt mushroom, and the scapula has a fan-shaped or skirt-like shape with a diameter of about 1 cm to 3 cm, and the surface has dense white, gray or grayish brown hairs. The girth is divided by the number of wrinkles. Fruiting body tissue is leather and shrinks when dry or wet. The wrinkles are white or grayish white, and the ends of the wrinkles are smooth and double. There is no stand, and a part of gad lives on attachment to the host. Spores are aspheric, 5 ~ 6 ㎛ × 4 ~ 5 ㎛, with smooth surface and light color. Form consultation is fleshy. The cyst is spindle-shaped, with no horns at the top, and the length is 60 ㎛ to 80 ㎛. It is a buhyeongseong mushroom that breaks up or overlaps on dead wood or living tree bark all the seasons and disintegrates the tree. It occurs from spring to autumn, forming a cluster of overlapping groups. Compounds showing various activities were found from the skim mushroom and the like. For example, there were found exopolysaccharide (EPS) having anti-inflammatory activity, shizostatin (squalene synthase inhibitor), shizofilane schizophyllan) were found.

According to one embodiment of the present invention, the chiostatin or a derivative thereof may include, but is not limited to, a substance represented by the following formula (1);

[Chemical Formula 1]

.

.

Wherein R ₁ to R ₃ are each independently selected from the group consisting of hydrogen, oxygen, a hydroxyl group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted cycloalkyl group, An unsubstituted alkoxy group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryloxy group, or a substituted or unsubstituted alkoxycarbonyl group, and n may be a number of 1 to 6, But is not limited to.

According to one embodiment of the present invention, the chiostatin or derivative thereof may include, but is not limited to, a substance represented by the following formula (2);

(2)

.

.

The material represented by the formula (2) is a white powder and has a molecular formula of C ₂₀ H ₃₀ O ₄ and has a molecular weight of 334.

Substances represented by the above general formula (2) EI-MS m / z 333.0 [ MH] - has a mass spectrum of the.

Material represented as the above general formula (2) _{ppm (600 MHz, CD 3 OD} ) 6.72 (s, H-2), 2.79 (t, J = 7.56, H-3), 2.18 (m, H-5), 5.16 ( t, J = 7.56, H- 6), 1.59 (s, 7-CH 3), 1.97 (t, H-8), 2.07 (m, H-9), 5.11 (t, J = 6.87, H-10 ), 1.59 (s, 11- CH 3), 1.97 (t, H-12), 2.07 (m, H-13), 5.09 (t, J = 6.87, H-14), 1.59 (s, 15-CH ₃ ) and 1.66 (s, H-16).

Material represented as the above general formula (2) _{ppm (600 MHz, CD 3 OD} ) 169.1 (C-1), 128.4 (C-2), 148.7 (C-3), 170.2 (3-COOH), 28.9 (C-4 ), 28.8 (C-5) , 124.5 (C-6), 137.4 (C-7), 16.2 (7-CH 3), 40.9 (C-8), 27.8 (C-9), 125.5 (C-10 ), 136.0 (C-11) , 16.3 (11-CH 3), 41.0 (C-12), 27.9 (C-13), 125.6 (C-14), 132.2 (C-15), 17.9 (15-CH ₃ ) and 26.1 (C-16), respectively.

The substance represented by the formula (2) was identified as chizostatin by the above-mentioned results.

According to one embodiment of the present invention, the chiostatin or a derivative thereof may include, but is not limited to, a substance represented by the following formula (3);

(3)

.

.

The material represented by the formula (3) is a colorless oil and has a molecular formula of C ₂₁ H ₃₆ O ₆ and has a molecular weight of 384.

The material represented by Formula 3 has a mass spectrometry spectrum of EI-MS m / z 407.0 [M + Na] < ⁺ >.

Material represented as the formula (3) _{ppm (600 MHz, CD 3 OD} ) 5.23, 5.16 (dd, J = 11, 17.2, H-1), 6.03 (dd, J = 11, 17.9, H-2), 1.33 _{(s, 3-CH 3)} , 1.64 (t, J = 8.25, H-4), 2.07 (m, H-5), 5.11 (t, J = 6.87, H-6), 1.60 (s, 7- _{CH 3), 1.97 (t,} J = 8.25, H-8), 2.04 (m, H-9), 5.09 (t, J = 6.87, H-10), 1.60 (s, 11-CH 3), 1.67 (s, H-12), 4.59 (s, H-1 '), 3.75 (d, J = 3.4, H-2'), 3.43 (dd, J = 3.4, 9.28, H-3 '), 3.57 ( t, J = 9.28, H-4 '), 3.11 (m, H-5'), 3.69, 3.80 (m, H-6 ').

Material represented as the formula (3) _{ppm (600 MHz, CD 3 OD} ) 115.1 (C-1), 144.4 (C-2), 81.3 (C-3), 23.9 (3-CH 3), 41.4 (C- 4), 27.9 (C-5 ), 125.9 (C-6), 136.1 (C-7), 16.3 (7-CH 3), 40.9 (C-8), 23.7 (C-9), 125.6 (C- 10), 132.2 (C-11 ), 17.9 (11-CH 3), 26.0 (C-12), 96.6 (C-1 '), 74.2 (C-2'), 75.7 (C-3 '), 66.5 (C-4 '), 78.0 (C-5'), and 63.0 (C-6 ').

The substance represented by the above formula (3) was identified as the novel compound SC-3 by the above results.

According to one embodiment of the present invention, the chiostatin or a derivative thereof may include, but is not limited to, a substance represented by the following Chemical Formula 4;

[Chemical Formula 4]

.

.

The material represented by Formula 4 is a colorless oil having a molecular formula of C ₁₅ H ₂₆ O and having a molecular weight of 222.

The material represented by Formula 4 has a mass spectrometry spectrum of EI-MS m / z 245.1 [M + Na] < ⁺ >.

Material represented as the above formula (4) _{ppm (600 MHz, CD 3 OD} ) 5.19 (dd, J = 1.37, 17.53, H-1), 5.91 (dd, J = 11, 17.18, H-2), 1.25 (s _{, 3-CH 3), 1.50} (m, H-4), 2.06 (m, H-5), 5.10 (m, H-6), 1.60 (s, 7-CH 3), 1.97 (m, H- 8), 2.02 (m, H -9), 5.03 (dd, J = 1.37, 11, H-10), 1.60 (s, 11-CH 3), 1.67 (s, 1H magnetic resonance in the H-12) Lt; / RTI >

Material represented as the above formula (4) _{ppm (600 MHz, CD 3 OD} ) 112.1 (C-1), 146.5 (C-2), 74.0 (C-3), 27.7 (3-CH 3), 43.6 (C- 4), 27.9 (C-5 ), 125.9 (C-6), 136.0 (C-7), 16.1 (7-CH 3), 41.0 (C-8), 23.8 (C-9), 125.6 (C- 10), it refers to the carbon nuclear magnetic resonance spectrum of the 132.3 (C-11), 17.9 (11-CH 3), 26.0 (C-12).

The substance represented by the above formula (4) was identified as the novel compound nerodilol by the above-mentioned results.

According to one embodiment of the present invention, the chiostatin or a derivative thereof may include, but is not limited to, a substance represented by the following formula (5);

[Chemical Formula 5]

.

.

The material represented by Formula 5 is a colorless oil having a molecular formula of C ₁₇ H ₂₆ O ₅ and having a molecular weight of 310.

The material represented by Formula 5 has a mass spectrometry spectrum of EI-MS m / z 309.0 [MH] < ^{- &} gt ;.

Material represented as the formula 5 _{ppm (600 MHz, CD 3 OD} ) 6.63 (s, H-2), 2.67 (t, J = 8.25, H-4), 2.17 (m, H-5), 5.21 ( t, J = 6.87, H- 6), 1.61 (s, 7-CH 3), 1.97 (t, J = 7.56, H-8), 2.08 (m, H-9), 5.14 (t, J = 6.87 a hydrogen nuclear magnetic of H-10), 1.60 (s , 11-CH 3), 2.02 (m, H-12), 1.62 (s, H-13), 3.51 (t, J = 6.87, H-14) Resonance spectrum.

Material represented as the formula 5 _{ppm (600 MHz, CD 3 OD} ) 176.9 (C-1), 131.1 (C-2), 145.9 (C-3), 177.4 (3-COOH), 30.5 (C-4 ), 29.2 (C-5) , 126.4 (C-6), 135.7 (C-7), 16.4 (7-CH 3), 41.0 (C-8), 27.8 (C-9), 125.9 (C-10 ), 135.6 (C-11) , 16.2 (11-CH 3), 37.1 (C-12), 32.1 (C-13), it represents a carbon nuclear magnetic resonance spectrum of the 62.8 (C-14).

The substance represented by the above formula 5 was identified as the novel compound SC-1 by the above-mentioned results.

According to one embodiment of the present invention, the chiostatin or derivative thereof may include, but is not limited to, a substance represented by the following formula (6);

[Chemical Formula 6]

.

.

The material represented by the formula (6) is a colorless oil and has a molecular formula of C ₂₀ H ₃₀ O ₅ and has a molecular weight of 350.

The substance represented by the above formula (6) has a mass spectrometry spectrum of EIMS m / z 349.0 [MH] ^- .

Material represented as Formula 6 _{ppm (600 MHz, CD 3 OD} ) 6.72 (s, H-2), 2.79 (t, J = 7.56, H-3), 2.18 (m, H-5), 5.16 ( t, J = 7.56, H- 6), 1.60 (s, 7-CH 3), 1.98 (t, J = 7.56, H-8), 2.08 (m, H-9), 5.13 (t, J = 6.87 , H-10), 1.61 ( s, 11-CH 3), 2.02 (t, J = 7.56, H-12), 2.13 (m, H-13), 5.39 (t, J = 6.87, H-14) , 1.64 (s, 15-CH ₃ ), 3.91 (s, H-16).

The material represented by the above formula 6 is represented by the following formula: ppm (600 MHz, CD ₃ OD) 169.0 (C-1), 128.4 (C-2), 148.7 ), 28.8 (C-5) , 124.5 (C-6), 137.4 (C-7), 16.2 (7-CH 3), 40.9 (C-8), 27.8 (C-9), 125.8 (C-10 ), 136.0 (C-11) , 16.3 (11-CH 3), 40.6 (C-12), 27.6 (C-13), 126.8 (C-14), 135.9 (C-15), 13.9 (15-CH ₃ ) and 69.2 (C-16), respectively.

The substance represented by the above formula (6) was identified as the novel compound SC-2-1 by the above results.

According to a second aspect of the present invention, there is provided a method for cultivating a skim mushroom strain on a medium; Obtaining a first extract from the cultured skim mushroom strain using a first solvent; And extracting chizostatin or a derivative thereof from the first extract using a second solvent.

Hereinafter, the manufacturing method will be described with reference to FIG.

The skim mushroom strain is cultured on a medium (S100).

According to one embodiment of the present invention, the medium may be a PDA (potato dextrose agar), a PDA (potato dextrose broth), a SDA (sabouraud dextrose agar), a DSA (dextrose starch agar) , CDA (czapek dox agar), or CMC (carboxyl methyl cellulose), but the present invention is not limited thereto.

Preferably, the cultured skim mushroom strain is cultured on a PDA medium, and then the cultured skim mushroom strain is cultured on a PDB medium using a cork roller. However, the present invention is not limited thereto.

Next, a first extract is obtained from the cultured skim mushroom strain using a first solvent (S200).

According to one embodiment of the present invention, the first solvent may be selected from the group consisting of water, acetone, C ₁ -C ₄ alcohol or a mixed solvent thereof, and combinations thereof, but is not limited thereto.

Then, chizostatin or a derivative thereof is extracted from the first extract using a second solvent (S300).

According to one embodiment of the present invention, the second solvent may include, but is not limited to, an organic solvent.

Preferably, the second solvent is selected from the group consisting of hexane, chloroform, methanol, ethyl acetate, and combinations thereof, but is not limited thereto.

According to one embodiment of the present invention, the extraction of the chiostatin or derivative thereof may be performed by extraction, distribution of water, or chromatography, but is not limited thereto.

Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are for illustrative purposes only and are not intended to limit the scope of the present invention.

[Example 1] Culture of skim mushroom strain and obtaining of culture extract of Staphylococcus aureus strain

Rhizoma mushroom strain was inoculated on PDA (potato starch 4.0 g / L, dextrose 20.0 g / L, agar 15.0 g / L) medium and cultured at 27 ° C for 15 days. Then, the mycelia of the mycelial tip were inoculated on a PDB (potato starch 4.0 g / L, dextrose 20.0 g / L) medium using a cork borer and cultured at 27 ° C for 4 weeks. The cultured skim mushroom strain was immersed in acetone for 1 day. Thereafter, the cultured skim mushroom strain immersed in acetone was extracted at room temperature to obtain a culture extract of A. mushroom strain.

[Example 2] Preparation of chloroform extract

The culture extract of A. mushroom strain of Example 1 was concentrated to remove acetone. Thereafter, the cultured extract of Schirmer mushroom strain was separated by extraction with hexane to separate the water layer and the hexane layer. The water layer was extracted with chloroform to separate into a water layer and a chloroform layer, and as a result, a chloroform extract was prepared.

[Example 3] Extraction of chizostatin or its derivative

The chloroform extract of Example 2 was subjected to silica gel chromatography using methanol as an eluent. Thereafter, the eluate was subjected to MPLC using methanol having a concentration of 50% as a mobile phase, thereby obtaining shyostatin and fractions. The fractions were subjected to sephadex LH-20 column chromatography using prep-HPLC and methanol having a concentration of 70% as a mobile phase to obtain SC-1 and SC-2-1. The fraction was subjected to silica gel chromatography using methanol as an eluent. Then, the eluate was subjected to sephadex LH-20 column chromatography using methanol as a mobile phase to obtain SC-3 and nerodilol.

Two-dimensional NMR spectra including ¹ H, ¹³ C, COZY (Correlation Spectroscopy) and HMBC (Heteronuclear Multiple Bond Connectivity) were measured to identify the chemical structure of the compound.

[Experimental Example 1]

In order to investigate the antimicrobial activity against phytopathogenic fungi, the minimum inhibitory concentration (MIC) of chinostatin and SC-3 of Example 3 was measured, and the results are shown in Table 1.

In this experiment, Rhizoctonia solani, Pyhtium sp. And Botrytis cinerea, a gray mold germ, were used, and the fungus was cultured at 27 DEG C for 2 to 5 days.

Minimum inhibitory concentration [MIC (占 퐂 / ml)] Chizostatin SC-3 Rhizoctonia solani 100 100 Pyhtium sp. 100 100 Botrytis cinerea 100 -

As a result, as shown in Table 1, Rhizoctonia solani, Pyhtium sp. And exhibited antimicrobial activity against Botrytis cinerea, a gray mold disease germ.

[Experimental Example 2]

In order to investigate the antimicrobial activity against the bacterium, the chiostatin of Example 3 was tested using the paper disk method, the disk was treated with the concentration-specific sample, and the results are shown in Table 2.

Staphylococcus aureus and Bacillus subtilis were used as the test microorganisms in the above experiment, and the diameters (mm) of the growth inhibition rings, which were cultured at 37 ° C for 24 hours, were measured.

Diameter of growth inhibition ring (mm) 200 [mu] g 100 [mu] g 50 [mu] g 10 [mu] g 5 [mu] g Bacillus subtilis 5.0 ± 0.8 3.3 ± 0.6 2.6 ± 0.1 - - Staphylococcus aureus 12.3 ± 0.4 8.3 ± 0.0 7.6 ± 0.1 3.2 ± 0.1 1.0 ± 0.4

As a result, as shown in Table 2 and Fig. 2, shizostatin showed strong antibacterial activity against Staphylococcus aureus and antibacterial activity against Bacillus subtilis.

It will be understood by those of ordinary skill in the art that the foregoing description of the embodiments is for illustrative purposes and that those skilled in the art can easily modify the invention without departing from the spirit or essential characteristics thereof. It is therefore to be understood that the above-described embodiments are illustrative in all aspects and not restrictive. For example, each component described as a single entity may be distributed and implemented, and components described as being distributed may also be implemented in a combined form.

The scope of the present invention is defined by the appended claims rather than the detailed description, and all changes or modifications derived from the meaning and scope of the claims and their equivalents should be construed as being included within the scope of the present invention.

Claims (12)

An antimicrobial composition, comprising a cultured extract of Rhizoma mushroom strain containing schizostatin or a derivative thereof.
The method according to claim 1,
Wherein the chiostatin or derivative thereof comprises a substance represented by the following formula (1);
[Chemical Formula 1]

Wherein R ₁ to R ₃ are each independently selected from the group consisting of hydrogen, oxygen, a hydroxyl group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted cycloalkyl group, A substituted or unsubstituted alkoxy group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryloxy group, or a substituted or unsubstituted alkoxycarbonyl group,
Wherein n is a number from 1 to 6;
The method according to claim 1,
Wherein the chiostatin or derivative thereof comprises a substance represented by the following Chemical Formula 2;
(2)

.
The method according to claim 1,
Wherein the chiostatin or derivative thereof comprises a substance represented by the following general formula (3);
(3)

.
The method according to claim 1,
Wherein the chiostatin or derivative thereof comprises a substance represented by the following formula (4);
[Chemical Formula 4]

.
The method according to claim 1,
Wherein the shzostatin or a derivative thereof comprises a substance represented by the following formula (5);
[Chemical Formula 5]

.
The method according to claim 1,
Wherein the shzostatin or a derivative thereof comprises a substance represented by the following formula (6);
[Chemical Formula 6]

.
Culturing the skimmed mushroom strain on a medium;
Obtaining a first extract from the cultured skim mushroom strain using a first solvent; And
Extracting chizostatin or a derivative thereof from the first extract using a second solvent
≪ / RTI >
9. The method of claim 8,
The medium may be selected from the group consisting of PDA (potato dextrose agar), PDA (potato dextrose broth), SDA (sabouraud dextrose agar), DSA (dextrose starch agar), MM ≪ / RTI > CMC (carboxyl methyl cellulose) medium.
9. The method of claim 8,
Wherein the first solvent is selected from the group consisting of water, acetone, C ₁ -C ₄ alcohols or mixed solvents thereof, and combinations thereof.
9. The method of claim 8,
Lt; RTI ID = 0.0 > 1, < / RTI > wherein the second solvent comprises an organic solvent.
9. The method of claim 8,
Wherein the extracting of the chiostatin or derivative thereof is carried out by extraction, dispensation of water, or chromatography.

Images